Home > Haematology > EHA 2019 > Lymphoid Malignancies > Exciting survival data for ibrutinib vs placebo in treatment-naïve, early-stage CLL

Exciting survival data for ibrutinib vs placebo in treatment-naïve, early-stage CLL

Presented By
Dr Petra Langerbeins, University of Cologne, Germany
Conference
EHA 2019
Trial
Phase 3, CLL12
Patients with early-stage, asymptomatic, newly diagnosed chronic lymphocytic leukaemia (CLL) showed improved survival outcomes with ibrutinib monotherapy compared with placebo, according to results from phase 3 CLL12 study presented by Dr Petra Langerbeins (University of Cologne, Germany). “So far, treatment of asymptomatic, early-stage CLL patients has not been proven beneficial; ibrutinib is a Bruton tyrosine kinase inhibitor with impressive clinical efficacy in advanced or relapsed CLL that has not been tested in treatment-naïve, early-stage CLL,” Dr Langerbeins explained. To address this gap, Dr Langerbeins and the German CLL Study Group conducted the double-blind, randomised, placebo-controlled, phase 3 CLL12 trial evaluating whether ibrutinib prolonged event-free survival (EFS; primary endpoint) in patients with early-stage CLL and increased risk of progressi...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on